EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieLeitlinieOpen Access

Price and Affordability of Heart Failure Guideline Directed Medical Therapy in Venezuela: A Cross Sectional Observational Study

Karim J Gebran-Chedid iD, Diana De Oliveira-Gomes iD, Gabriela Lombardo iD, Maria Carolina Bacci-Padron iD, David A Forero-Peña iD

Global Heart · 2025

DOI: 10.5334/gh.1474 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Global Heart, 2025. Verfasst von Karim J Gebran-Chedid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New York Medical College/Metropolitan Hospital Center, New York, NY, USA. Hauptthemen laut MEDLINE: Heart Failure, Practice Guidelines as Topic. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure (HF) impacts over 56 million people worldwide, with significantly higher mortality rates in low and low-middle-income countries (LIC/LMICs). Despite the effectiveness of guideline-directed medical therapy (GDMT) for HF with reduced ejection fraction (HFrEF), its use remains limited in LIC/LMICs due to limited availability and affordability. These barriers are particularly pressing in Venezuela’s context, as the country faces an ongoing crisis.

Objective

Describe price and affordability of HF Guideline Directed Medical Therapy at optimal dosages in Venezuela.

Methods

We conducted a cross-sectional analysis from December 2023 to January 2024, surveying prices of HF GDMT medications across 13 major pharmacy networks in Venezuela. Medications analyzed included ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). Affordability was defined and calculated using the World Health Organization/Health Action International (WHO/HAI) methodology, comparing the median costs of one month of HF GDMT at optimal dosages to the lowest-paid government worker’s (LPGW) daily wages. Other comparisons of price affordability were made against the mean daily salary of managers, professional and non-professional workers in the country.

Results

The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively. meaning LPGW and elderly receiving retirement stipends would need between 506 to 2421 paid work days to cover one month of treatment at optimal dosages.

Conclusion

Based on the WHO/HAI methodology all HF GDMT regimens were deemed unaffordable in Venezuela. Similar affordability challenges exist in other LIC/LMICs countries highlighting the need for global advocacy and policy action to address financial barriers to access guideline-based heart failure care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePractice Guidelines as TopicHumansVenezuelaCross-Sectional StudiesAngiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsMale

Stichwörter der Autor:innen

Venezuelaguideline directed medical therapyheart failuremedication affordability

Substanzen

Angiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, New York Medical College/Metropolitan Hospital Center, New York, NY, USA.
  • Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela.
  • "Luis Razetti" School of Medicine (Alumni), Universidad Central de Venezuela, Caracas, Venezuela.
  • Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

ORCID-Profile: Karim J Gebran-Chedid, Diana De Oliveira-Gomes, Gabriela Lombardo, Maria Carolina Bacci-Padron, David A Forero-Peña

Zitieren

APA

Gebran-Chedid, K. J., De Oliveira-Gomes, D., Lombardo, G., Bacci-Padron, M. C., & Forero-Peña, D. A. (2025). Price and Affordability of Heart Failure Guideline Directed Medical Therapy in Venezuela: A Cross Sectional Observational Study. Global Heart. https://doi.org/10.5334/gh.1474

Vancouver

Gebran-Chedid KJ, De Oliveira-Gomes D, Lombardo G, Bacci-Padron MC, Forero-Peña DA. Price and Affordability of Heart Failure Guideline Directed Medical Therapy in Venezuela: A Cross Sectional Observational Study. Global Heart. 2025. doi:10.5334/gh.1474

BibTeX
@article{GebranChedid2025,
  author = {Gebran-Chedid, Karim J and De Oliveira-Gomes, Diana and Lombardo, Gabriela and Bacci-Padron, Maria Carolina and Forero-Peña, David A},
  title = {Price and Affordability of Heart Failure Guideline Directed Medical Therapy in Venezuela: A Cross Sectional Observational Study},
  journal = {Global Heart},
  year = {2025},
  doi = {10.5334/gh.1474}
}
Kostenlos starten →